| Jul 31 |
Sanofi unit Genzyme sues Sarepta alleging patent infringement in Duchenne drug
|
| Jul 30 |
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
|
| Jul 29 |
RBC Capital raises Sarepta to outperform ahead of Elevidys launch
|
| Jul 29 |
Sarepta Therapeutics Poised for 'Significant Launch Inflection' Amid Positive Elevidys Feedback, RBC Says
|
| Jul 29 |
5 Biotech Stocks to Bet On Bright Industry Prospects
|
| Jul 29 |
Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results
|
| Jul 24 |
Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
|
| Jul 21 |
This market expert warns real estate woes may not be limited to commercial — 3 'idiosyncratic' stocks he likes
|
| Jul 19 |
Wall Street Analysts Believe Sarepta Therapeutics (SRPT) Could Rally 38.04%: Here's is How to Trade
|
| Jul 17 |
Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There'
|
